Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lentinan-adriamycin bonding medicine and preparation method thereof

A technology of lentinan and doxorubicin, which is applied in pharmaceutical formulations, antitumor drugs, drug combinations, etc., can solve the problems of unfavorable bonded drug practical application, lack of doxorubicin release, cumbersome preparation process, etc., and achieve excellent synergy. , good biocompatibility, enhanced efficacy

Active Publication Date: 2014-03-26
CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The Chinese patent whose publication number is CN102406946A discloses a kind of macromolecular bonded drug, first, polyethylene glycol monomethyl ether, carboxylated doxorubicin derivatives, 1-(3-dimethylaminopropyl)-3-ethyl Carbodiimide hydrochloride and N-hydroxysuccinimide react in an organic solvent to obtain a reaction mixture, and then add poly (L-lysine) or chitosan to the reaction mixture to obtain Polymer doxorubicin-bonded drug; Chinese patent publication No. 101234205A discloses a polymer doxorubicin-bonded drug with targeting function, which is assembled by mixing two polyethylene glycol-polylactic acid block copolymers The polylactic acid chain end of the first polyethylene glycol-polylactic acid block copolymer is connected with doxorubicin, and the polyethylene glycol chain end of the second polyethylene glycol-polylactic acid block copolymer is connected with There is lactose, which has a sustained release function; lactose has a targeting function, which can realize the targeted delivery of doxorubicin, so the doxorubicin-bonded drug can be released slowly in tumor tissue; however, the above two bonded drugs are due to The chemical bond between the bonded polymer compound and the drug molecule is too stable, so there are problems such as low drug loading and lack of intelligence in the release of doxorubicin
Biomaterials (Vol.31, p1360-1371, 2010) disclosed a carboxyl group modified by polyethylene glycol monomethyl ether and cis-3-carboxyglutaconic anhydride on the surface amino groups of polyamide-amine dendrimers The polymer doxorubicin-bonded drug obtained by doxorubicin can be quickly released under the acidic conditions of tumor tissues and cells, thereby realizing the intelligence of drug release, but the carrier used in the bonded drug The material is a polyamide-amine dendrimer, and its preparation process is cumbersome and its biocompatibility is poor, which is not conducive to the practical application of the bonded drug.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lentinan-adriamycin bonding medicine and preparation method thereof
  • Lentinan-adriamycin bonding medicine and preparation method thereof
  • Lentinan-adriamycin bonding medicine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0031] The present invention also provides a preparation method of lentinan-doxorubicin bonded drug, comprising:

[0032] mixing and reacting the buffer solution in which doxorubicin hydrochloride is dissolved with lentinan to obtain a lentinan-doxorubicin bonded drug having a structure of formula (I);

[0033] Or mix and react the buffer solution in which doxorubicin hydrochloride is dissolved with lentinan and sodium cyanoborohydride to obtain the lentinan-doxorubicin bonded drug with the structure of formula (II).

[0034] The lentinan-doxorubicin bonded drug with the structure of formula (I) is prepared according to the following method:

[0035] First, doxorubicin hydrochloride is dissolved in a buffer solution to obtain a mixed solution; the doxorubicin hydrochloride has the structure shown in formula (III):

[0036]

[0037] The buffer solution is preferably an acetate buffer solution, specifically a sodium acetate-acetic acid buffer solution; the pH value of the bu...

Embodiment 1～8

[0056] Prepare an acetate buffer solution with pH=5, take 5 mL of the prepared buffer solution and place them in 8 round-bottomed flasks respectively, add 0.05 g of doxorubicin hydrochloride to each flask, stir and dissolve in the dark, and then According to the dosage ratio in Table 1, add lentinan and sodium cyanoborohydride to each flask, the number average molecular weight of the lentinan is 4208g.mol -1 , then seal each reaction bottle, according to the reaction conditions in Table 1, react in the dark for 52h, after the reaction, adjust the pH of each reaction solution to 7.4 with sodium bicarbonate solution, then use a dialysis bag with a molecular weight cut-off of 7000Dalton for dialysis for 48h, filter Freeze-dried to obtain the lentinan-doxorubicin bonded drug respectively, the experimental results are shown in Table 1, and Table 1 is the reaction conditions and yields of the lentinan-doxorubicin bonded drug prepared in Examples 1 to 8 of the present invention, where...

Embodiment 9～16

[0062] Prepare an acetate buffer solution with pH=5, take 5 mL of the prepared buffer solution and place them in 8 round-bottomed flasks respectively, add doxorubicin hydrochloride to each flask according to the ratio in Table 2, and keep away from light. After stirring and dissolving, according to the dosage ratio in Table 2, add lentinan and sodium cyanoborohydride to each flask, the number average molecular weight of the lentinan is 4208g.mol -1 , then seal each reaction bottle, and react in the dark at 40°C for 52h. After the reaction, adjust the pH of each reaction solution to 7.4 with sodium bicarbonate solution, then dialyze with a dialysis bag with a molecular weight cut-off of 7000Dalton for 48h, filter and freeze-dry to obtain Lentinan-Adriamycin bonded drug, the experimental results are shown in Table 2, Table 2 is the reaction conditions and yields of Lentinan-Adriamycin bonded drug prepared in Examples 9-16 of the present invention, wherein, i represents Lentinan ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Number average molecular weightaaaaaaaaaa
Number average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a lentinan-adriamycin bonding medicine which has the structure shown in the formula (I) or formula (II) in the Specification, wherein n refers to the polymerization degree of lentinan, and is not less than 10 and not greater than 3278. According to the invention, lentinan and adriamycin are used as raw materials, or lentinan, sodium cyanoborohydride and adriamycin are used as raw materials to prepare two types of lentinan-adriamycin bonding medicines; as the lentinan used as the raw material has excellent biological activity and biocompatibility, and small toxic and side effects, the prepared lentinan-adriamycin bonding medicines have excellent biological activity and biocompatibility, and lower toxic and side effects; in addition, the lentinan and adriamycin are connected through oxime bonds, and can be quickly released in the tumor tissue or cells with the lower pH value, so that the efficacy of the lentinan-adriamycin bonding medicine is improved; the reduced lentinan-adriamycin bonding medicine which has the structure shown in the formula (II) in the Specification is more stable in performance, and the adriamycin can be released more slowly, so that the ideal long-acting treatment is realized.

Description

technical field [0001] The invention relates to the technical field of chemically bonded drugs, in particular to a lentinan-doxorubicin bonded drug and a preparation method thereof. Background technique [0002] Doxorubicin, also known as 1,4-hydroxydaunorubicin, 1,4-hydroxydaunomycin, doxorubicin, hydroxyerythrobimycin, is an anthracycline antibiotic with high efficiency and broad-spectrum anti-tumor The drug is a cell cycle non-specific drug and has the strongest effect on the S phase. It mainly inserts into the DNA of the cell, thereby triggering topoisomerase II to destroy the tertiary structure of the DNA to exert its drug effect. So far, doxorubicin has been considered as a powerful clinical chemotherapy drug, mainly for the treatment of solid tumors such as liver cancer, lung cancer, gastric cancer, breast cancer, ovarian cancer, bladder cancer, and thyroid cancer. [0003] At present, clinical chemotherapy of doxorubicin mainly exerts its drug effect through intrave...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/48A61K31/704A61K31/715A61P35/00
Inventor 丁建勋许维国庄秀丽陈学思
Owner CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com